201942-90-7

Basic information

• Product Name: (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid
• Synonyms: (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid;(4R)-2-(2-hydroxyphenyl)thiazolidine-4-carboxylic acid
• CAS NO: 201942-90-7
• Molecular Formula: C₁₀H₁₁NO₃S
• Molecular Weight: 225.26424
• Mol File: 201942-90-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid(201942-90-7)
• EPA Substance Registry System: (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid(201942-90-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 201942-90-7(Hazardous Substances Data)

Usage

General Description

The chemical (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid is a compound that belongs to the class of thiazolidine carboxylic acids. It is a chiral molecule, meaning it has a specific 3D arrangement of atoms that gives it a unique spatial orientation. (R)-2-(2-Hydroxyphenyl)thiazolidine-4-carboxylic acid has a thiazolidine ring structure with a hydroxyphenyl group and a carboxylic acid group attached to it. It is commonly used in the synthesis of various pharmaceutical compounds and is also being studied for its potential biological activities, particularly in the context of its interaction with certain biological receptors or enzymes.

Upstream product

• 52-89-1 l-cysteine hydrochloride 
• 90-02-8 salicylaldehyde 
• 52-90-4 L-Cysteine 

Downstream Products

• 75966-38-0 (2R,2'R,4R,4'R)-3,3'-(3,3'-dithiodipropionyl)bis<2-(2-acetoxyphenyl)-4-thiazolidinecarboxylic acid> 
• 161153-16-8 (2R,4R)-3-(tert-butoxycarbonyl)-2-(2-hydroxyphenyl)-thiazolidine-4-carboxylic acid 
• 1297309-33-1 3-phenylacetyl-(2RS,4R)-2-(2-hydroxy-phenyl)-thiazolidine-4-carboxylic acid 
• 72679-49-3 (R)-2-(2-Hydroxy-phenyl)-3-(4-mercapto-butyryl)-thiazolidine-4-carboxylic acid 
• 69570-69-0 (R)-2-(2-Hydroxy-phenyl)-3-((S)-3-mercapto-2-methyl-propionyl)-thiazolidine-4-carboxylic acid 
• 82562-53-6 (2R,4R)-trans-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid 
• 80830-42-8 fentiapril 
• 72679-47-1 (4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropanoyl)-4-thiazolidinecarboxylic acid 
• 72679-45-9 (R)-2-(2-Hydroxy-phenyl)-3-(2-mercapto-acetyl)-thiazolidine-4-carboxylic acid 
• 82562-54-7 (2R,4R)-3-acetyl-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid 
• 82562-48-9 (2S,4R)-3-acetyl-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid 
• 96631-35-5 (2R,4R)-3-<3-(2-carboxyethyldithio)propionyl>-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid 
• 72679-50-6 (R)-3-((S)-3-Benzoylsulfanyl-2-methyl-propionyl)-2-(2-hydroxy-phenyl)-thiazolidine-4-carboxylic acid 

Relevant articles and documents

Turn-on fluorescent probe for Zn2+ ions based on thiazolidine derivative

In this study, simple on–off fluorescent/UV–visible (UV–Vis) probes were easily prepared using 2-(2-hydroxyphenyl)thiazolidine-4-carboxylic acid (Sen-1) and/or 2-(2-hydroxy-5-nitrophenyl)thiazolidine-4-carboxylic acid (Sen-2) for fast detection of Zn

GLUCOSE-SENSITIVE PEPTIDE HORMONES

The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of Lp and Lj, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in v/vo,the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.

Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics

Purple acid phosphatases (PAPs) are metalloenzymes that catalyse the hydrolysis of phosphate esters under acidic conditions. Their active site contains a Fe(III)Fe(II) metal centre in mammals and a Fe(III)Zn(II) or Fe(III)Mn(II) metal centre in plants. In humans, elevated PAP levels in serum strongly correlate with the progression of osteoporosis and metabolic bone malignancies, which make PAP a target suitable for the development of chemotherapeutics to combat bone ailments. Due to difficulties in obtaining the human enzyme, the corresponding enzymes from red kidney bean and pig have been used previously to develop specific PAP inhibitors. Here, existing lead compounds were further elaborated to create a series of inhibitors with Ki values as low as ～30 μM. The inhibition constants of these compounds were of comparable magnitude for pig and red kidney bean PAPs, indicating that relevant binding interactions are conserved. The crystal structure of red kidney bean PAP in complex with the most potent inhibitor in this series, compound 4f, was solved to 2.40 ? resolution. This inhibitor coordinates directly to the binuclear metal centre in the active site as expected based on its competitive mode of inhibition. Docking simulations predict that this compound binds to human PAP in a similar mode. This study presents the first example of a PAP structure in complex with an inhibitor that is of relevance to the development of anti-osteoporotic chemotherapeutics.